Publications
Detailed Information
Down-regulation of HIF-1α by oncolytic reovirus infection independently of VHL and p53
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cho, I-R | - |
dc.contributor.author | Koh, S. S. | - |
dc.contributor.author | Min, H-J | - |
dc.contributor.author | Park, E-H | - |
dc.contributor.author | Jhun, B. H. | - |
dc.contributor.author | Yoo, Y. H. | - |
dc.contributor.author | Johnston, R. N. | - |
dc.contributor.author | Chung, Y-H | - |
dc.contributor.author | Youn, H. D. | - |
dc.contributor.author | Jeong, S. H. | - |
dc.contributor.author | Ratakorn, S. | - |
dc.date.accessioned | 2012-06-05T05:37:07Z | - |
dc.date.available | 2012-06-05T05:37:07Z | - |
dc.date.issued | 2010-05 | - |
dc.identifier.citation | CANCER GENE THERAPY; Vol.17 5; 365-372 | ko_KR |
dc.identifier.issn | 0929-1903 | - |
dc.identifier.uri | https://hdl.handle.net/10371/76847 | - |
dc.description.abstract | Many oncolytic viruses are currently being tested as potential cancer therapeutic agents. To be effective, these viruses must replicate and propagate efficiently through the tumor mass. However, it is possible that the hypoxia that characterizes many tumors may be an obstacle to viral therapy because of its inhibition of viral replication and propagation. We, therefore, decided to test how oncolytic reovirus and its target cells respond to hypoxia. We found that reovirus infection suppresses hypoxia inducible factor (HIF)-1α protein levels (but not transcript abundance) in colon cancer HCT116 cells under CoCl(2) or hypoxia. Reovirus infection was able to reduce HIF-1α levels in both von Hippel Lindau (VHL)-/- renal carcinoma A498 and p53-/- HCT116 cells, indicating that the decrease of HIF-1α mediated by reovirus requires neither VHL nor p53 proteins. However, treatment with the inhibitor MG132 restored HIF-1α levels, suggesting that reovirus-induced HIF-1α decrease needs proteosomal activity. A498 VHL-/- cells with constitutive expression of HIF-1α were relatively resistant to reovirus-induced apoptosis when compared with A498 VHL+/+ cells. However, we found that the use of YC-1 to target HIF-1α promoted reovirus-induced apoptosis in A498 VHL-/- cells. Accordingly, we propose that reovirus may be used together with YC-1 as a potential therapeutic agent against chemoresistant or radioresistant tumors that are hypoxic and show increased levels of HIF-1α. Cancer Gene Therapy (2010) 17, 365-372; doi:10.1038/cgt.2009.84; published online 15 January 2010 | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | NATURE PUBLISHING GROUP | ko_KR |
dc.subject | reovirus | ko_KR |
dc.subject | hypoxic inducible factor-1α | ko_KR |
dc.subject | renal carcinoma | ko_KR |
dc.subject | YC-1 | ko_KR |
dc.subject | von Hippel Lindau (VHL) | ko_KR |
dc.title | Down-regulation of HIF-1α by oncolytic reovirus infection independently of VHL and p53 | ko_KR |
dc.type | Article | ko_KR |
dc.identifier.doi | 10.1038/cgt.2009.84 | - |
dc.citation.journaltitle | CANCER GENE THERAPY | - |
dc.description.citedreference | Park EH, 2009, CANCER GENE THER, V16, P453, DOI 10.1038/cgt.2008.95 | - |
dc.description.citedreference | Cheng J, 2007, CELL, V131, P584, DOI 10.1016/j.cell.2007.08.045 | - |
dc.description.citedreference | Sun HL, 2007, ONCOGENE, V26, P3941, DOI 10.1038/sj.onc.1210169 | - |
dc.description.citedreference | Kim M, 2007, J MICROBIOL, V45, P187 | - |
dc.description.citedreference | Kim HY, 2007, EXP CELL RES, V313, P1866, DOI 10.1016/j.yexcr.2007.03.009 | - |
dc.description.citedreference | Liu YV, 2007, MOL CELL, V25, P207, DOI 10.1016/j.molcel.2007.01.001 | - |
dc.description.citedreference | Hwang IIL, 2006, J VIROL, V80, P10712, DOI 10.1128/JVI.01014-06 | - |
dc.description.citedreference | Roe JS, 2006, MOL CELL, V22, P395, DOI 10.1016/j.molcel.2006.04.006 | - |
dc.description.citedreference | Kong XG, 2006, MOL CELL BIOL, V26, P2019, DOI 10.1128/MCB.26.6.2019-2028.2006 | - |
dc.description.citedreference | Dang DT, 2006, CANCER RES, V66, P1684, DOI 10.1158/0008-5472.CAN-05-2887 | - |
dc.description.citedreference | Escuin D, 2005, CANCER RES, V65, P9021, DOI 10.1158/0008-5472.CAN-04-4095 | - |
dc.description.citedreference | Norman KL, 2005, DRUG DISCOV TODAY, V10, P847 | - |
dc.description.citedreference | Yang WQ, 2004, CLIN CANCER RES, V10, P8561 | - |
dc.description.citedreference | Ikeda Y, 2004, AURIS NASUS LARYNX, V31, P407, DOI 10.1016/j.anl.2004.07.003 | - |
dc.description.citedreference | Norman KL, 2004, P NATL ACAD SCI USA, V101, P11099 | - |
dc.description.citedreference | Stoeltzing O, 2004, J NATL CANCER I, V96, P946, DOI 10.1093/jnci/djh168 | - |
dc.description.citedreference | Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367 | - |
dc.description.citedreference | Wakisaka N, 2004, MOL CELL BIOL, V24, P5223, DOI 10.1128/MCB.24.12.5223-5234.2004 | - |
dc.description.citedreference | Bardos JI, 2004, BIOESSAYS, V26, P262, DOI 10.1002/bies.20002 | - |
dc.description.citedreference | Yoo YG, 2003, J BIOL CHEM, V278, P39076, DOI 10.1074/jbc.M305101200 | - |
dc.description.citedreference | Giaccia A, 2003, NAT REV DRUG DISCOV, V2, P803, DOI 10.1038/nrd1199 | - |
dc.description.citedreference | Janssen HLA, 2003, J HEPATOL, V39, P414, DOI 10.1016/S0168-8278(03)00265-4 | - |
dc.description.citedreference | Yeo EJ, 2003, J NATL CANCER I, V95, P516 | - |
dc.description.citedreference | Welsh SJ, 2003, MOL CANCER THER, V2, P235 | - |
dc.description.citedreference | Hirasawa K, 2003, CANCER RES, V63, P348 | - |
dc.description.citedreference | Alain T, 2002, BLOOD, V100, P4146, DOI 10.1182/blood-2002-02-0503 | - |
dc.description.citedreference | Ring CJA, 2002, J GEN VIROL, V83, P491, DOI 10.1099/vir.0.18098-0 | - |
dc.description.citedreference | Russel FGM, 2002, ANNU REV PHYSIOL, V64, P563 | - |
dc.description.citedreference | Clarke P, 2001, ONCOGENE, V20, P6910 | - |
dc.description.citedreference | Jaakkola P, 2001, SCIENCE, V292, P468 | - |
dc.description.citedreference | Chun YS, 2001, BIOCHEM PHARMACOL, V61, P947 | - |
dc.description.citedreference | Hockel M, 2001, J NATL CANCER I, V93, P266 | - |
dc.description.citedreference | Tanimoto K, 2000, EMBO J, V19, P4298 | - |
dc.description.citedreference | Maxwell PH, 1999, NATURE, V399, P271 | - |
dc.description.citedreference | Coffey MC, 1998, SCIENCE, V282, P1332 | - |
dc.description.citedreference | Teng CM, 1997, EUR J PHARMACOL, V320, P161 | - |
dc.description.citedreference | Levine AJ, 1997, CELL, V88, P323 | - |
dc.description.citedreference | NIBERT ML, 1991, J VIROL, V65, P1960 | - |
dc.description.citedreference | DILLER L, 1990, MOL CELL BIOL, V10, P5772 | - |
dc.description.citedreference | ROSEN L, 1963, AM J HYG, V77, P29 | - |
dc.description.tc | 0 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.